ReviewClinical infectious diseases : an official publication of the Infectious Diseases Society of America2022
Clinical Efficacy and Safety of Albendazole and Other Benzimidazole Anthelmintics for Rat Lungworm Disease (Neuroangiostrongyliasis): A Systematic Analysis of Clinical Reports and Animal Studies.
Review in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 31 citations in OpenAlex.
- High-Entropy Catalyst Activated Molecular Oxygen for Oxidative Coupling Under Ambient Conditions.Angewandte Chemie (International ed. in English) · 2026Article
- An Outbreak of Neuroangiostrongyliasis (Rat Lungworm Disease) in Hawai'i: Evidence Supporting the Early Use of Albendazole-Corticosteroid Co-Therapy.The American journal of tropical medicine and hygiene · 2026Article
- Albendazole-doxycycline combination therapy alleviates MRI- and pathology-evident neuroinflammation and restores IL-33/GFAP balance in mouse neuroangiostrongyliasis.Parasites & vectors · 2026Article
- Article
- Central nervous system infection by Angiostrongylus cantonensis in children: experience from Guangdong, China.BMC infectious diseases · 2025Article
- Structural Exploitation of Cinnarizine Identified Novel Drug-Like Anthelmintic Agents AgainstACS infectious diseases · 2025Article
- Synthesis and SARs of benzimidazoles: insights into antimicrobial innovation (2018-2024).RSC advances · 2025Review
- Scaffolds imparting anthelmintic activity: recent advancements and SAR studies.Molecular diversity · 2025Review
- Successful Management of Angiostrongylus Cantonensis-Induced Eosinophilic Meningitis Using Albendazole-Corticosteroid Therapy: A Case Report With Serial Cytokine and CSF Monitoring.Case reports in infectious diseases · 2025Article
- Albendazole ameliorates aerobic glycolysis in myofibroblasts to reverse pulmonary fibrosis.Journal of translational medicine · 2024Article
- Detection of rat lungworm (Angiostrongylus cantonensis) infection by real-time PCR from the peripheral blood of animals: a preliminary study.Parasitology research · 2024Article
- Immunodiagnostic Detection of Angiostrongylus cantonensis Exposure on Hawaii Island Using Isogeographic 31-kDa Antigen.The American journal of tropical medicine and hygiene · 2023Article
- Angie-LAMP for diagnosis of human eosinophilic meningitis using dog as proxy: A LAMP assay for Angiostrongylus cantonensis DNA in cerebrospinal fluid.PLoS neglected tropical diseases · 2023Article
- Neuroangiostrongyliasis: Updated Provisional Guidelines for Diagnosis and Case Definitions.Pathogens (Basel, Switzerland) · 2023Article
- Management of Rat Lungworm Disease (Neuroangiostrongyliasis) Using Anthelmintics: Recent Updates and Recommendations.Pathogens (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The safety and efficacy of benzimidazole anthelmintics for the treatment of rat lungworm disease (neuroangiostrongyliasis) have been questioned regardless of numerous experimental animal studies and clinical reports. In this review, 40 of these experimental animal studies and 104 clinical reports are compiled with a focus on albendazole. Among the 144 articles involving an estimated 1034 patients and 2561 animals, 4.1% were inconclusive or vague regarding the use of benzimidazoles. Of the remaining 138 articles, 90.5% found benzimidazoles to be safe and effective (885 patients, 2530 animals), 4.3% as safe but ineffective (73 patients, 3 animals), and 5.0% caused adverse reactions (7 patients, 28 animals). Among those clinical reports that described a confirmed diagnosis of neuroangiostrongyliasis in which albendazole monotherapy was used, 100% reported high efficacy (743 patients, 479 animals). In those where albendazole-corticosteroid co-therapy was used, 97.87% reported it to be effective (323 patients, 130 animals).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.